← Search & browse all drugs
BLOOD AND BLOOD FORMING ORGANS › OTHER HEMATOLOGICAL AGENTS › OTHER HEMATOLOGICAL AGENTS › Drugs used in hereditary angioedema
donidalorsen
B06AC09
Forms & Strengths
- Solution for injection: 1.5 mg/mL
- Single-dose prefilled syringe: 1.5 mg/1 mL
Adult Dosing
- Initial dose: 1.5 mg/kg intravenously
- Maintenance dose: 1.5 mg/kg every 14 days
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
Indications
- Treatment of acute hepatic porphyria attacks
- Prevention of acute hepatic porphyria attacks
Mechanism of Action
- Small interfering RNA that inhibits aminolevulinic acid synthase 1
- Decreases hepatic production of neurotoxic heme precursors
Contraindications
- Hypersensitivity to donidalorsen or any component of the formulation
Adverse Reactions
- Injection site reactions
- Pyrexia
- Fatigue
- Nausea
- Headache
Drug Interactions
- None well-documented, but potential for interaction with other hepatotoxic or porphyrin-inducing drugs
Curated Content: Needs Vetting Before Put to Clinical Use